Our research note today highlights the opportunities available from Basilea's existing portfolio and pipeline. Basilea addresses the...

The H1 period at Basilea was notable for another strong performance from the anti-fungal Cresemba (isavuconazole). Underlying growth was...

This morning, Basilea announced the start of its second Phase 3 trial for fosmanogepix, its first-in-class antifungal for the treatment...